{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T16:09:03Z","timestamp":1791216543839,"version":"4.1.0"},"reference-count":9,"publisher":"Baishideng Publishing Group Inc.","issue":"32","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["WJG"],"published-print":{"date-parts":[[2008]]},"DOI":"10.3748\/wjg.14.5098","type":"journal-article","created":{"date-parts":[[2008,9,12]],"date-time":"2008-09-12T04:06:06Z","timestamp":1221192366000},"page":"5098","source":"Crossref","is-referenced-by-count":22,"title":["Serious drug-induced liver disease secondary to ezetimibe"],"prefix":"10.3748","volume":"14","author":[{"given":"Jos\u00e9","family":"Castellote","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Ariza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosa","family":"Rota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Girbau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Xiol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2060","reference":[{"key":"ref1","unstructured":"Jackevicius CA, Tu JV, Ross JS, Ko DT, Krumholz HM. Use of ezetimibe in the United States and Canada. N Engl J Med 2008;358:1819-1828."},{"key":"ref2","unstructured":"Civeira F. Guidelines for the diagnosis and management of heterozygous familial hypercholesterolemia. Atherosclerosis 2004;173:55-68."},{"key":"ref3","unstructured":"Bhardwaj SS, Chalasani N. Lipid-lowering agents that cause drug-induced hepatotoxicity. Clin Liver Dis 2007;11:597-613, vii."},{"key":"ref4","unstructured":"Andrade RJ, Robles M, Fernandez-Castaner A, Lopez-Ortega S, Lopez-Vega MC, Lucena MI. Assessment of drug-induced hepatotoxicity in clinical practice: a challenge for gastroenterologists. World J Gastroenterol 2007;13:329-340."},{"key":"ref5","unstructured":"Maddrey WC. Drug-induced hepatotoxicity: 2005. J Clin Gastroenterol 2005;39:S83-S89."},{"key":"ref6","unstructured":"van Heyningen C. Drug-induced acute autoimmune hepatitis during combination therapy with atorvastatin and ezetimibe. Ann Clin Biochem 2005;42:402-404."},{"key":"ref7","unstructured":"Stolk MF, Becx MC, Kuypers KC, Seldenrijk CA. Severe hepatic side effects of ezetimibe. Clin Gastroenterol Hepatol 2006;4:908-911."},{"key":"ref8","unstructured":"Liu Q, Tobias H, Petrovic LM. Drug-induced liver injury associated with ezetimibe therapy. Dig Dis Sci 2007;52:602-605."},{"key":"ref9","unstructured":"Sabate M, Ibanez L, Perez E, Vidal X, Buti M, Xiol X, Mas A, Guarner C, Forne M, Sola R. Risk of acute liver injury associated with the use of drugs: a multicentre population survey. Aliment Pharmacol Ther 2007;25:1401-1409."}],"container-title":["World Journal of Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.wjgnet.com\/1007-9327\/full\/v14\/i32\/5098.htm","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,11,21]],"date-time":"2017-11-21T04:01:52Z","timestamp":1511236912000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.wjgnet.com\/1007-9327\/full\/v14\/i32\/5098.htm"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008]]},"references-count":9,"journal-issue":{"issue":"32","published-print":{"date-parts":[[2008]]}},"URL":"https:\/\/doi.org\/10.3748\/wjg.14.5098","relation":{},"ISSN":["1007-9327"],"issn-type":[{"value":"1007-9327","type":"print"}],"subject":[],"published":{"date-parts":[[2008]]}}}